Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Shuping Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6433-8412; OpenAlex author ID A5100641234. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system. Co-author DOI 10.1186/s12967-025-06304-w↗
  2. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. Last author DOI 10.1016/j.phrs.2021.106040↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaolong Liu · 1 shared paper, 2025 · strength 0.28
  2. Yulan Li · 1 shared paper, 2025 · strength 0.28
  3. Xueyan Zhang · 1 shared paper, 2025 · strength 0.28
  4. Yungen Xu · 1 shared paper, 2022 · strength 0.17
  5. Shihui Huang · 1 shared paper, 2022 · strength 0.17
  6. Shiqi Wu · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.